Current FDA labels document these patterns in detail: Wegovy (semaglutide) lists nausea (44% vs 16% placebo), vomiting (25% vs 6%), diarrhea (30% vs 16%), constipation (24% vs 11%), abdominal distension and eructation, with severe GI events in 4.1% versus 0.9% placebo.[2] Zepbound (tirzepatide) lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, eructation, and gastroesophageal reflux disease among common adverse reactions, with severe GI disease as a Warnings and Precautions item.[3] Both labels include postmarketing reports of ileus, severe constipation including fecal impaction, and acute kidney injury related to dehydration from severe GI symptoms
This anti-inflammatory peptide isnt a miracle cure
Prostate cancer is the most common hormone-dependent cancer in men, and the fifth leading cause of cancer-related mortality, partly owing to a lack of knowledge about the mechanisms that lead to aggressive castration-resistant forms
Brouwer, R
References to specific companies are for illustrative purposes only and should not be construed as investment advice or a recommendation to buy or sell any security
